Advancing Nanotechnology in Targeted Cancer Therapy: From Passive Targeting to Smart Delivery Systems

Bibliographic Information
Authors: Fahmy A.M.
Journal: Premier Journal of Science
Publisher: Premier Science
Publication Date: 31 January 2025
Volume / Issue: Volume 6
Article No.: 100052
ISSN: 30499011
DOI: 10.70389/PJS.100052
Scopus: View on Scopus
Document Type: Review
Access: All Open Access; Hybrid Gold Open Access
Authors and Affiliations
Fahmy A.M., Parasitology Department, Theodore Bilharz Research Institute, Cairo, Egypt
Abstract
With the help of nanotechnology, cancer treatment can be optimized while still keeping the level of side effects low. This includes recent advances that treat cancer on a molecular level, including mechanisms for targeting the delivery of therapeutic substances and, last, new intelligent delivery systems. Active targeting approaches by surface modification have increased tumor cell ingestion and decreased the required dose for treatment. Yet, enhanced permeability and retention, which is its capital effect, is functional as well, but at a very low impact, as studies show only 0.7% of the injected nanoparticles accumulate in the tumors. FDA-approved nanoformulations using liposomes and polymers exhibit significant clinical benefits owing to their improved pharmacokinetics and less toxicity. Significant obstacles impede market entry, including low production scalability, complex regulatory frameworks, and development costs exceeding $2.5 billion. The existence of biological impediments, notably the blood-brain barrier and intricate tumor microenvironments, exacerbates the challenges of drug administration. The advances in artificial intelligence and smart delivery systems have enhanced the design and efficacy of nanocarriers. Machine learning algorithms can predict the success rate in drug delivery with 92% accuracy when the process is continuously monitored, which enables dynamic treatment adjustment. Along with these, quantum dots and DNA nanostructures represent new technologies offering more targeted and personalized approaches to cancer treatment. However, there are some hurdles in need of overcoming, such as current regulation and manufacturing. © 2025, Premier Science. All rights reserved.
Keywords
Blood-brain barrier; Enhanced permeability and Retention (EPR); Liposomal formulations; Nanocarriers; Stimuli-responsive systems
Citation Information
Scopus Citations: 2
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
